For the first time in nearly three decades, there's a new treatment option for people who have an advanced form of the most common type of bladder cancer called Urothelial. Cleveland Clinic physician Petros Grivas says the U.S. Food and Drug Administration recently fast tracked the drug that is designed to boost the immune system.
Urothelial can spread during or after certain chemotherapy treatments. Prior to the approval, there were not treatment options if surgery and standard chemotherapy failed.
